Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, Hubei Province, China.
World J Gastroenterol. 2017 Nov 28;23(44):7888-7898. doi: 10.3748/wjg.v23.i44.7888.
To determine the association of circulating miR-125a/b expression with the risk and disease severity of Crohn's disease (CD), and with inflammatory cytokines.
Plasma samples were collected from patients with active CD (A-CD), or CD in remission (R-CD) and from healthy controls (HCs). The levels of the inflammatory cytokines interleukin-17 (IL-17), tumour necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) were measured by enzyme-linked immunosorbent assay. The expression of miR-125a/b was assessed by quantitative polymerase chain reaction (qPCR).
Twenty-nine A-CD patients, 37 R-CD patients, and 37 HCs were included in the study. Plasma miR-125a expression was decreased in A-CD patients compared with that in R-CD patients ( < 0.001) and HCs ( < 0.001). miR-125a expression levels enabled the differentiation of A-CD from R-CD patients [area under curve (AUC) = 0.854] and from HCs (AUC = 0.780), whereas miR-125b expression did not. miR-125a was negatively correlated with C-reaction protein (CRP) ( = 0.017), erythrocyte sedimentation rate (ESR) ( = 0.026), Crohn's disease activity index (CDAI) ( = 0.003), IL-17 ( = 0.015), and TNF-α ( = 0.004) in A-CD patients. Furthermore, miR-125a was negatively associated with CRP ( = 0.038) and CDAI ( = 0.021) in R-CD patients. Regarding miR-125b, no association with CRP, CDAI, IL-17, TNF-α, or IFN-γ was found in A-CD or in R-CD patients. miR-125a levels gradually increased in A-CD patients who achieved clinical remission ( = 0.009) after 3-mo treatment, whereas they remained unchanged among patients who failed to achieve remission. No changes in miR-125b expression were detected in remission or non-remission patients after treatment.
Circulating miR-125a but not miR-125b is decreased in patients with active disease status and negatively correlates with disease severity and inflammatory cytokines in patients with CD.
确定循环 miR-125a/b 表达与克罗恩病（CD）的风险和疾病严重程度以及与炎症细胞因子的关联。
收集活动期 CD（A-CD）患者、缓解期 CD（R-CD）患者和健康对照者（HCs）的血浆样本。采用酶联免疫吸附试验（ELISA）检测白细胞介素-17（IL-17）、肿瘤坏死因子-α（TNF-α）和干扰素-γ（IFN-γ）的水平。采用实时聚合酶链反应（qPCR）评估 miR-125a/b 的表达。
本研究纳入了 29 例 A-CD 患者、37 例 R-CD 患者和 37 例 HCs。与 R-CD 患者（<0.001）和 HCs（<0.001）相比，A-CD 患者的血浆 miR-125a 表达降低。miR-125a 表达水平能够区分 A-CD 患者与 R-CD 患者（AUC=0.854）和 HCs（AUC=0.780），而 miR-125b 表达则不能。miR-125a 与 A-CD 患者的 C 反应蛋白（CRP）（=0.017）、红细胞沉降率（ESR）（=0.026）、克罗恩病活动指数（CDAI）（=0.003）、白细胞介素-17（=0.015）和肿瘤坏死因子-α（=0.004）呈负相关。此外，miR-125a 与 R-CD 患者的 CRP（=0.038）和 CDAI（=0.021）也呈负相关。关于 miR-125b，在 A-CD 或 R-CD 患者中，均未发现与 CRP、CDAI、IL-17、TNF-α或 IFN-γ相关。在接受 3 个月治疗后，达到临床缓解的 A-CD 患者的 miR-125a 水平逐渐升高（=0.009），而未缓解的患者的 miR-125a 水平则保持不变。治疗后，缓解和未缓解患者的 miR-125b 表达均未发生变化。
在活动期疾病状态的患者中，循环 miR-125a 降低，与疾病严重程度和 CD 患者的炎症细胞因子呈负相关，但 miR-125b 则不然。
